Presenting Cutting-Edge Cardiac Innovations at AHA 2025
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS), a pioneer in wearable medical devices, has recently announced its involvement in the American Heart Association (AHA) Scientific Sessions 2025. This event is taking place from November 7 to 10, showcasing a pivotal advancement in cardiac care through a late-breaking science presentation.
Understanding the ACE-PAS Trial
During the AHA event, Kestra will unveil primary results from the crucial ACE-PAS Trial, officially known as the Post-Approval Study of a Next Generation Wearable Cardioverter Defibrillator System. This significant presentation is set to occur on November 10 at 8:44 a.m. CT.
Largest Study of Its Kind
The ACE-PAS Trial is unique in its scope, with over 20,000 patients enrolled to evaluate the real-world effectiveness of the next-generation wearable cardioverter defibrillator system. Being the largest prospective study of its kind, the ACE-PAS focuses on critical factors such as shock conversion success and rates of inappropriate shocks.
Key Findings and Impacts
The trial is designed to gather extensive data that includes initial shock conversion success and the average daily wear time. These insights illustrate the growing impact of wearable technology in improving outcomes for patients at risk of sudden cardiac events. By being featured in AHA's late-breaking science program, this research highlights the essential role of data-driven approaches in shaping modern cardiac care.
Insights from Leadership
Brian Webster, the President and CEO of Kestra Medical Technologies, expressed pride in being selected for such a prestigious presentation. He emphasized how this recognition underscores the importance of the ACE-PAS study and the company's innovative technology. As the landscape of cardiac recovery continuously evolves, Kestra is redefining monitoring and treatment through advanced digital health integration.
Explore Innovative Solutions at AHA
Attendees at the AHA 2025 can visit Kestra's booth (#4617) to experience the Kestra Cardiac Recovery System. This system incorporates the ASSURE® Wearable Cardioverter Defibrillator, combining reliable patient safety features with essential clinical insights. This integration allows healthcare providers to enhance guideline-directed therapies and support patients' long-term recovery journeys.
Engagement at the Event
Beyond their late-breaking presentation, Kestra will facilitate live demonstrations and engaging discussions throughout the conference. Their booth will feature an immersive experience that highlights their commitment to connected and data-driven cardiac recovery solutions, showcasing the future of heart health technologies.
About Kestra Medical Technologies
Kestra Medical Technologies is dedicated to enhancing patient outcomes in cardiovascular care by leveraging intuitive and connected therapeutic interventions. Their innovative approaches aim to transform how patients manage cardiovascular conditions while aiming to improve healthcare delivery across the board. For further details, please visit www.kestramedical.com.
Frequently Asked Questions
What is the ACE-PAS Trial?
The ACE-PAS Trial evaluates the effectiveness of a next-generation wearable cardioverter defibrillator by studying its real-world application with over 20,000 patients.
When will the results be presented?
The primary results from the ACE-PAS Trial will be presented on November 10 at 8:44 a.m. CT during the AHA Scientific Sessions 2025.
What is the significance of this study?
This study is significant because it represents the largest prospective study on wearable cardioverter defibrillators, demonstrating their efficacy in real-world settings and broadening understanding of sudden cardiac event management.
How does Kestra's technology improve patient care?
Kestra's technology integrates monitoring and therapeutic solutions that provide healthcare professionals with data-driven insights, enhancing patient safety and recovery strategies.
Where can I learn more about Kestra Medical Technologies?
For more information about their innovative solutions and commitment to cardiac care, please visit www.kestramedical.com.
